A systematic mapping review of neuropathic pain therapeutics from marine organisms
Journal of Pharmacy & Pharmacognosy Research · 01.09.2026 · 14 (5) · 2844
DOI: 10.56499/jppres_14.5.2844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmacognosy Research, online erschienen am 01.09.2026. Verfasst von Bárbara B. Garrido-Suárez und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Context
Neuropathic pain remains difficult to treat because current therapies provide limited efficacy and are often associated with adverse effects. Marine organisms are a source of structurally diverse bioactives that may modulate pain-relevant molecular targets.
Aims
A systematic evidence map (SEM) was constructed to identify and characterize the antineuropathic potential of marine-derived bioactives, with emphasis on mechanisms of action, translational evidence, and limitations affecting therapeutic development.
Methods
A PRISMA-guided review was conducted in PubMed, Scopus, Web of Science, and ScienceDirect for studies published from January 2010 to April 2025. Preclinical in vivo studies, in vitro or in silico target-engagement studies, and clinical studies evaluating marine-derived compounds, extracts, fractions, or synthetic equivalents relevant to neuropathic pain were considered.
Results
Ninety-one studies were included. Most evidence was preclinical, and only three clinical reports were identified. The strongest translational evidence was associated with compounds derived from Conus species, particularly conotoxins, and with tetrodotoxin. Marine bioactives were reported to modulate voltage-gated sodium and calcium channels, nicotinic acetylcholine receptors, acid-sensing ion channels, transient receptor potential channels, G protein-coupled receptors, and neuroimmune pathways. Major translational barriers included limited selectivity across species, peptide instability, delivery constraints, incomplete safety profiling, and insufficient use of disease-relevant models.
Conclusions
Marine-derived bioactives constitute promising leads for mechanism-based neuropathic pain therapy. Future studies should prioritize human-target validation, disease-relevant models, blinded and adequately powered experimental designs, long-term safety assessment, and scalable synthesis or delivery strategies.
Zitieren
APA
Garrido-Suárez, B. B., Garrido, G., Zamora-Fernández, O. A., Hernández-Balmaseda, I. H., Ardiles-Rivera, A., Fernández-Pérez, M. D., & Rodeiro-Guerra, I. (2026). A systematic mapping review of neuropathic pain therapeutics from marine organisms. Journal of Pharmacy & Pharmacognosy Research, 14(5), 2844. https://doi.org/10.56499/jppres_14.5.2844
Vancouver
Garrido-Suárez BB, Garrido G, Zamora-Fernández OA, Hernández-Balmaseda IH, Ardiles-Rivera A, Fernández-Pérez MD, et al. A systematic mapping review of neuropathic pain therapeutics from marine organisms. Journal of Pharmacy & Pharmacognosy Research. 2026;14(5):2844. doi:10.56499/jppres_14.5.2844
BibTeX
@article{GarridoSurez2026,
author = {Garrido-Suárez, Bárbara B. and Garrido, Gabino and Zamora-Fernández, Oscar A. and Hernández-Balmaseda, Ivones Hernández-Balmaseda and Ardiles-Rivera, Alejandro and Fernández-Pérez, Miguel D. and Rodeiro-Guerra, Idania},
title = {A systematic mapping review of neuropathic pain therapeutics from marine organisms},
journal = {Journal of Pharmacy & Pharmacognosy Research},
year = {2026},
volume = {14},
number = {5},
pages = {2844},
doi = {10.56499/jppres_14.5.2844}
}
EUVIMED